Drug Discovery
Drug Discovery covers where GLP-1 came from and where it’s going. Single-agonist (semaglutide), dual-agonist (tirzepatide), triple-agonist (retatrutide in trials), and oral small-molecule (orforglipron, just approved as Foundayo) — each represents a different bet on maximizing efficacy while managing side effects. We explain mechanisms and track the late-stage pipeline.
Do GLP-1 Drugs Cause Cancer? Honest Answer.
A boxed warning, scary headlines, anxious social-media posts. The real cancer evidence on GLP-1 drugs is more nuanced — and…
Latest in Drug Discovery
GLP-1 in 2026: 5 Big Changes Coming Soon
A new pill, a far more powerful drug in trials, a Medicare pilot, a tightening line on compounding. The GLP-1…
Compounded Semaglutide from $147/month
More from Drug Discovery
Rybelsus: GLP-1 in a Daily Pill (Yes, Really)
Affiliate disclosure: This article contains affiliate links. We may earn commission when you purchase through…
Zepbound: For Weight Loss AND Sleep Apnea
Affiliate disclosure: This article contains affiliate links. We may earn commission when you purchase through…
Mounjaro (2026): Dose, Cost, and Side Effects
Affiliate disclosure: This article contains affiliate links. We may earn commission when you purchase through…
Wegovy (2026): Dose, Cost, and the Pill Version
Affiliate disclosure: This article contains affiliate links. We may earn commission when you purchase through…
Ozempic (2026): The Complete Dose & Cost Guide
Affiliate disclosure: This article contains affiliate links. We may earn commission when you purchase through…